Why carry out this study? |
Nail psoriasis is a chronic, difficult-to-treat condition affecting around half of patients with psoriasis and more studies are needed that compare the effectiveness of different biologics for patients with nail psoriasis. |
Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year, prospective, non-interventional cohort study and this analysis compares the effectiveness of approved biologics in improving nail psoriasis for patients up to month 12 in a real-world setting. |
What was learned from the study? |
The findings of this real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail psoriasis had significantly faster and more substantial improvements in nail psoriasis up to month 6 in the anti-interleukin (IL)-17A cohort compared to the other biologics cohort. |
Of the individual biologics studied, ixekizumab showed the highest numerical improvements in nail psoriasis at month 12. |
These results may support physicians in their treatment decisions for patients with psoriasis and concomitant nail psoriasis and may serve as a foundation for further real-world studies of this difficult-to-treat condition. |
Open Access 22.04.2024 | Brief Report
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
Erschienen in: Dermatology and Therapy | Ausgabe 5/2024